AI Article Synopsis
- - The study investigates the roles of LRP5 and sclerostin in placentas of mothers with gestational diabetes mellitus (GDM) and their potential links to umbilical sclerostin levels and health outcomes for both mothers and infants.
- - In a sample of 26 GDM and 34 non-GDM mothers, researchers analyzed placental sclerostin and LRP5 expression, revealing higher levels of both in GDM cases, as well as positive correlations with maternal body mass index and glucose levels.
- - The findings suggest that increased expressions of placental sclerostin and LRP5 in GDM pregnancies might reflect an adaptive response to metabolic changes, highlighting their significance in bone metabolism and diabetes susceptibility
Article Abstract
Introduction: The low-density lipoprotein receptor-related protein 5 (LRP5) and its inhibitor sclerostin, are key components of bone metabolism and potential contributors to type 2 diabetes mellitus susceptibility. This study aims at evaluating the expression of placental LRP5 and sclerostin in pregnancies with gestational diabetes mellitus (GDM) and investigate possible associations with umbilical sclerostin concentrations and clinical outcomes in mothers and their neonates.
Methods: Twenty-six GDM-mothers and 34 non-GDM mothers of Caucasian origin and their neonates admitted in a gynecology and obstetrics department of a university hospital were included in this study. Demographic data and maternal fasting glucose concentrations (24-28 weeks of gestation) were retrieved from the patients' medical records. Placental LRP5 was determined by immunohistochemistry (IHC) and Western blotting analysis; placental sclerostin was determined by IHC. Umbilical serum sclerostin concentrations were measured by ELISA.
Results: Placental sclerostin IHC intensity values were positively correlated with LRP5 values as detected either by IHC (r = 0.529; P < .001) or Western blotting (r = 0.398; P = .008), with pregestational maternal body mass index values (r = 0.299; P = .043) and with maternal fasting glucose concentrations (r = 0.475; P = .009). Placental sclerostin and LRP5 were significantly greater in GDM compared with non-GDM placentas (histo-score: 65.08 ± 17.09 vs 11.45 ± 2.33, P < .001; 145.53 ± 43.74 vs 202.88 ± 58.65, P < .001; respectively).
Discussion: Sclerostin and LRP5 were detected in human placentas. The overexpression of placental sclerostin and LRP5 values in GDM compared with non-GDM pregnancies, as well as the positive association of placental sclerostin values with pregestational maternal body mass index and maternal fasting glucose concentrations may indicate the development of an adaptive mechanism in face of maternal hyperglycemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702852 | PMC |
| http://dx.doi.org/10.1210/clinem/dgad164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of 24-hydroxylated catabolism increases calcitriol and fibroblast growth factor 23 and alters calcium and phosphate metabolism in fetal mice.
JBMR Plus
May 2024
Faculty of Medicine - Endocrinology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, A1B 3V6, Canada.
Calcitriol circulates at low levels in normal human and rodent fetuses, in part due to increased 24-hydroxylation of calcitriol and 25-hydroxyvitamin D by 24-hydroxylase (CYP24A1). Inactivating mutations of cause high postnatal levels of calcitriol and the human condition of infantile hypercalcemia type 1, but whether the fetus is disturbed by the loss of CYP24A1 is unknown. We hypothesized that loss of in fetal mice will cause high calcitriol, hypercalcemia, and increased placental calcium transport.
View Article and Find Full Text PDFHuman Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies.
J Clin Endocrinol Metab
September 2023
Diabetes Mellitus and Metabolism Unit, ARETAION Hospital, Medical School, National and Kapodistrian University of Athens, GR-11528, Athens, Greece.
Article Synopsis
- - The study investigates the roles of LRP5 and sclerostin in placentas of mothers with gestational diabetes mellitus (GDM) and their potential links to umbilical sclerostin levels and health outcomes for both mothers and infants.
- - In a sample of 26 GDM and 34 non-GDM mothers, researchers analyzed placental sclerostin and LRP5 expression, revealing higher levels of both in GDM cases, as well as positive correlations with maternal body mass index and glucose levels.
- - The findings suggest that increased expressions of placental sclerostin and LRP5 in GDM pregnancies might reflect an adaptive response to metabolic changes, highlighting their significance in bone metabolism and diabetes susceptibility
Sclerostin stimulates angiogenesis in human endothelial cells.
Bone
August 2017
Department of Basic Medical Sciences, Neurosciences and Sense Organs, Section of Human Anatomy and Histology, University of Bari, Bari, Italy. Electronic address:
Sclerostin, negative regulator of bone formation, has been originally known as an osteocyte product. Recently, it has been also detected in hypertrophic chondrocytes, distinctive cells of avascular cartilage which is invaded by capillaries and then replaced by vascularized bone. Thus, we hypothesized that sclerostin, in addition to its role already known, may exert an angiogenic activity.
View Article and Find Full Text PDFUmbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates.
Eur J Endocrinol
March 2013
Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway.
Context: During pregnancy, changes occur in the maternal calcium homeostasis to fulfill fetal demand. We hypothesized that the fibroblast growth factor 23 (FGF23) system and Wnt signaling pathway are important for normal skeletal development in the offspring.
Aims: Circulating α-klotho, FGF23, sclerostin, and 25-hydroxyvitamin D (25(OH)D) at the fetal and maternal sides of the placenta were measured to investigate associations with newborn bone mass independent of maternal BMI, calcium and phosphate levels, placental weight, and birth weight.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!